letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...1112131415161718192021...100101»
  • ||||||||||  vepdegestrant (ARV-471) / Arvinas, Pfizer, Ibrance (palbociclib) / Pfizer
    Leveraging a pharmacokinetic/pharmacodynamic (PK/PD) model to guide dose optimization of palbociclib (palbo) in combination with vepdegestrant (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_1846;    
    P1/2, P3
    The PK/PD model simulation allows for relative comparison of Grade 4 neutropenia incidence and average palbo concentration between the planned reduced starting doses of palbo in the context of increased exposure relative to standard palbo dosing, i.e., without vepdegestrant. This simulation indicates a reduced dose of palbo (100 mg) in combination with vepdegestrant produces similar incidence of Grade 4 neutropenia and comparable average palbo concentration compared to historical reference providing additional support for the study lead-in of NCT05909397.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Comparison of clinical efficacy between letrozole + ribociclib vs. Fulvestrant + letrozole + ribociclib in Hormone receptor positive, HER2 negative metastatic breast cancer  (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_1591;    
    Selective estrogen receptor downregulator (SERD) such as elacestrant or fulvestrant is suggested as second-line treatment, but the progression-free survival (PFS) outcome of second-line treatment is reported up to 3.78 months in patients who harbour ESR1 mutation...If patients received adjuvant tamoxifen, patients with TFI less than 12 months can be also enrolled for the study...Secondary endpoint included PFS, overall survival (OS), emergence and frequency of ESR1 mutation, overall response rate (ORR) and clinical benefit rate (CBR). The analysis is planned after completion of 30 months of follow-up, which provides approximately 90% power to detect superiority 24 months-PFS rate assumed by Kaplan-Meier curve of letrozole + fulvestrant + ribociclib versus letrozole + ribociclib using a log-rank test, assuming a hazard ratio of 0.64 at a two-sided alpha of 0.2.
  • ||||||||||  letrozole / Generic mfg.
    Ketogenic diet and letrozole to inhibit PI3K signaling in ER+ breast cancer (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_1060;    
    For both groups, cell proliferation will be measured in a tumor biopsy obtained from the surgical specimen and compared with the pre-treatment diagnostic biopsy. Correlative studies will evaluate tumor markers of insulin/PI3K signaling before and after the intervention and between diet and control.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead
    Hiding in plain sight: A heterogeneous response in a patient with metastatic HR+/HER2- breast cancer (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_967;    
    10% of Patients in the Safety Population Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; Waterfall plot of best change rate in target-lesion size from baseline She tolerated one week of tamoxifen which was discontinued due to adverse effects...Patient was started on letrozole with lupron and palbociclib with disease control for two years until progression in the bone, prompting a switch of letrozole to fulvestrant with continued palbociclib...She was then started on single-agent paclitaxel...She opted to enroll into a Phase 1b/2 trial with sacituzumab govitecan-hziy in combination with a PARPi...A history of mixed response in the liver was concluded to be two coexisting neoplasms
  • ||||||||||  Real-World Data of Neuroendocrine Neoplasms of Breast (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_921;    
    Of these, 79 presented with localized disease, 18 were metastatic at presentation. 88 (91%) were invasive ductal carcinoma (IDC), and 64 (81%) were local disease at presentation and rest were metastatic.
  • ||||||||||  Which treatment is done in patients with metastatic breast cancer who received a prior treatment with CDK4/6 inhibitors? A real-world experience in a single italian Institution (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_788;    
    105 mBC patients, 32 of whom were treated with CD4/6 inhibitors plus letrozole and 73 treated with CDK4/6 inhibitors and fulvestrant were included in the study...1 (0.95%) patients was treated with a triplet chemotherapy regimen (cyclophosphamide+capecitabine +vinorelbine), 2 (1.9%) for whom the re-biopsy of the tumor resulted HER2 + were treated with taxol +pertuzumab +trastuzumab...The major part of them have been treated with chemotherapy alone or with combination of more chemotherapies. The evaluation of the patient response in relation to the different therapies is still ongoing as well as the effect of all the other therapies beyond the first line of treatment.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, BLU-222 / Blueprint Medicines
    Combination treatment with CDK2 inhibitor (BLU-222) and either palbociclib or ribociclib is synergistic in pre-clinical models of CDK4/6 inhibitor-resistant breast cancer (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_632;    
    The efficacy of BLU-222 as a single agent or in combination with palbociclib or ribociclib was also assessed in two PDX models (PR 1 and 2) from patients with acquired resistance (i.e. progressed following >6 months of treatment) to palbociclib plus letrozole treatment, and another two PDX models (PR 3 and 4) from patients who were intrinsically resistant (i.e. progressed following < 3 months of treatment) to palbociclib plus fulvestrant or letrozole, respectively. These results show robust activity of BLU-222 in combination with CDK4/6 inhibitors in breast cancer cell lines and PDX models resistant to CDK4/6 inhibitors, providing a strong rationale for advancing BLU-222 plus CDK4/6 inhibitor treatment to clinical development in HR-positive/HER2-negative breast cancer patients who have progressed on CDK4/6 inhibitors.
  • ||||||||||  Epidiolex (cannabidiol) / Jazz
    Evaluating Symptom Clusters in Patients with Breast Cancer Experiencing Aromatase Inhibitor-Associated Musculoskeletal Symptoms (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_551;    
    P2
    Though it is difficult to extrapolate results from a small population, the unexpected absence of co-occurring symptoms in this population raises additional questions about the interplay of AIMSS and other symptoms commonly reported in interventional AIMSS studies. Follow-up PRO data will be obtained in this clinical trial, allowing us to examine the impact of CBD use on pain, pain interference, and other patient-reported symptoms, as well as to explore which patients are more likely to obtain benefit from CBD treatment.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    CDK4/6 inhibitor-induced Interstitial Lung Disease (ILD) - A Case Series (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_476;    
    The overall risk of ILD was 1.6% in a meta-analysis of over 16,000 patients treated with CDK4/6 inhibitors while individual reported risk was 1%, 1.6% and 3% for palbociclib, ribociclib, and abemaciclib respectively...She started on palbociclib and letrozole and subsequently had 2 hospitalizations for acute hypoxemic respiratory failure with unremarkable infectious workup...The patient initially received taxol with near resolution of disease on imaging...Patient was switched to fulvestrant; and after 9 months she was diagnosed with stage IV tongue cancer and her breast cancer therapy was discontinued...It is important to identify early by performing a thorough workup, including a detailed history and physical exam, medication list review, infectious work-up, chest imaging, PFTs and pulmonology consultation. Publishing a set of standardized guidelines to diagnose and treat CDK4/6 inhibitor-induced ILD is necessary as more cases are identified.
  • ||||||||||  Reolysin (pelareorep) / Oncolytics, Andrus Reo
    T Cell Receptor Sequencing to Monitor Pelareorep-Induced Expansion of Tumor Infiltrating Lymphocytes (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_439;    
    Newly diagnosed HR+/HER2- eBC patients were enrolled into two cohorts: Cohort 1: pela + letrozole (n=10); and Cohort 2: pela + letrozole + atezolizumab (n=10). These results confirm the previously reported CelTIL results from AWARE-1 on pela-induced increases in TILs and demonstrate the expansion of these clones in both tumor and blood as a consequence of pela therapy for HR+/HER2- breast cancer.
  • ||||||||||  pruxelutamide (GT0918) / Kintor Pharma
    Proxalutamide plus Endocrine Therapies in Women with HR+/HER2-/AR+ Metastatic Breast Cancer: A Phase Ic Study (Stars at Night Ballroom 1-2) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_398;    
    These findings suggested favorable clinical outcomes and safety profiles of the combination of proxalutamide and fulvestrant in AR+/HR+/HER2- mBC patients who have progressed on the first-line therapy, and maybe with better efficacy in patients with lower AR/ER ratio. Trial registration: NCT20191063
  • ||||||||||  vepdegestrant (ARV-471) / Arvinas, Pfizer, Ibrance (palbociclib) / Pfizer
    Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER (Stars at Night Ballroom 1-2) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_395;    
    P1/2, P3
    The safety profile of vepdegestrant plus palbo was generally consistent with the known safety profiles of the 2 agents except for an increased occurrence of grade 3/4 neutropenia, which was readily managed with laboratory monitoring and dose reductions of palbo. There is an ongoing study lead-in to the global VERITAC-3 study (NCT05909397) that is evaluating 2 doses of palbo (100 mg and 75 mg) in combination with vepdegestrant 200 mg QD to determine the recommended phase 3 combination to compare with letrozole plus palbo as first-line treatment for ER+/HER2- advanced breast cancer.
  • ||||||||||  zanidatamab (ZW25) / Jazz
    Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer (Stars at Night Ballroom 1-2) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_351;    
    Neoadjuvant zanidatamab demonstrates significant preliminary efficacy, (pCR/RCB-1 64%) with a good safety profile in patients with stage I node negative HER2+ BC. An update of efficacy and safety of all patients will be presented at the time of meeting
  • ||||||||||  letrozole / Generic mfg.
    Tumor immune microenvironment modulates resistance to estrogen suppression in ER+ breast cancer (Stars at Night Ballroom 1-2) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_304;    
    We collected samples from 215 postmenopausal patients with stage I-III ER+ BC, treated with letrozole for 2-4 weeks, to induce ED...In contrast, ED-S tumors showed a more immunosuppressed milieu. The role of CXCL9, CXCL10 and CXCL11 in inducing resistance to ED warrants further investigation.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Letrozole in fertility treatment. (Pubmed Central) -  Nov 3, 2023   
    LTZ may be used as co-treatment in poor responders prior to in vitro fertilization/intracytoplasmic sperm injection. In addition, LTZ prior to frozen-thawed embryo transfer is increasingly used in women with normogonadotrophic oligo-anovulation.
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Evaluation of IM Letrozole ISM (clinicaltrials.gov) -  Nov 1, 2023   
    P1,  N=120, Active, not recruiting, 
    N=300 --> 400 Trial completion date: Sep 2023 --> Feb 2024 | Trial primary completion date: Sep 2023 --> Feb 2024